Knowledge Distillery

One of the immediate and ongoing neurological challenges posed by the COVID-19 pandemic is the management of patients who are undergoing immunotherapy…

The first 12 months of COVID-19: a timeline of immunological insights

A plea for equitable global access to COVID‐19 diagnostics, vaccination and therapy: the NeuroCOVID‐19 task Force of the European Academy of Neurology…

The chronic neuropsychiatric sequelae of COVID‐19: The need for a prospective study of viral impact on brain functioning

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus

Managing multiple sclerosis in the COVID19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia

Consensus statement of the International League against epilepsy and the International Federation of Clinical Neurophysiology

Our highlighted selection of Covid-related expert opinions from the scientific press for January 2022

Our highlighted selection of Covid-related expert opinions from the scientific press for February 2022

Disease-modifying therapies (DMT) for relapsing-remitting MS (RRMS) act on the immune system, suggesting a need for caution during the…

Coronavirus disease (COVID-19) appeared in December 2019 in the Chinese city of Wuhan and has quickly become a global pandemic.

Since the initial reports of a cluster of pneumonia cases of unidentified origin in Wuhan, China, in December 2019, the novel coronavirus that causes…